ACUT
Price
$0.24
Change
-$0.00 (-0.00%)
Updated
Dec 17 closing price
MOLN
Price
$5.30
Change
+$0.05 (+0.95%)
Updated
Dec 18 closing price
77 days until earnings call
Ad is loading...

ACUT vs MOLN

Header iconACUT vs MOLN Comparison
Open Charts ACUT vs MOLNBanner chart's image
Accustem Sciences
Price$0.24
Change-$0.00 (-0.00%)
Volume$323
CapitalizationN/A
Molecular Partners AG
Price$5.30
Change+$0.05 (+0.95%)
Volume$15.99K
CapitalizationN/A
ACUT vs MOLN Comparison Chart
Loading...
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MOLN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACUT vs. MOLN commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACUT is a Hold and MOLN is a Buy.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ACUT: $0.24 vs. MOLN: $5.30)
Brand notoriety: ACUT and MOLN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACUT: 9% vs. MOLN: 53%
Market capitalization -- ACUT: $2.75M vs. MOLN: $199.47M
ACUT [@Biotechnology] is valued at $2.75M. MOLN’s [@Biotechnology] market capitalization is $199.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACUT’s FA Score shows that 1 FA rating(s) are green whileMOLN’s FA Score has 0 green FA rating(s).

  • ACUT’s FA Score: 1 green, 4 red.
  • MOLN’s FA Score: 0 green, 5 red.
According to our system of comparison, MOLN is a better buy in the long-term than ACUT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACUT’s TA Score shows that 3 TA indicator(s) are bullish while MOLN’s TA Score has 2 bullish TA indicator(s).

  • ACUT’s TA Score: 3 bullish, 5 bearish.
  • MOLN’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, ACUT is a better buy in the short-term than MOLN.

Price Growth

ACUT (@Biotechnology) experienced а +0.04% price change this week, while MOLN (@Biotechnology) price change was -3.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.11%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was +0.25%.

Reported Earning Dates

MOLN is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (-7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MOLN($199M) has a higher market cap than ACUT($2.75M). MOLN YTD gains are higher at: 26.797 vs. ACUT (-61.307). ACUT has higher annual earnings (EBITDA): -1.74M vs. MOLN (-60.16M). MOLN has more cash in the bank: 144M vs. ACUT (9.37K). MOLN has higher revenues than ACUT: MOLN (6M) vs ACUT (0).
ACUTMOLNACUT / MOLN
Capitalization2.75M199M1%
EBITDA-1.74M-60.16M3%
Gain YTD-61.30726.797-229%
P/E RatioN/AN/A-
Revenue06M-
Total Cash9.37K144M0%
Total DebtN/A2.75M-
TECHNICAL ANALYSIS
Technical Analysis
ACUTMOLN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
72%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 16 days ago
74%
Bullish Trend 16 days ago
69%
Declines
ODDS (%)
Bearish Trend 9 days ago
82%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
77%
N/A
View a ticker or compare two or three
Ad is loading...
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MOLN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RSPKX24.48N/A
N/A
Victory RS Partners R
RCGTX14.54N/A
N/A
Virtus Zevenbergen Technology C
APFWX10.28-0.24
-2.28%
Artisan Value Income Investor
JTKRX14.14-0.40
-2.75%
JHancock Global Thematic Opps R6
OEGIX34.54-1.48
-4.11%
Invesco Discovery Mid Cap Growth R6